Literature DB >> 11006527

Protein aggregation in Huntington's and Parkinson's disease: implications for therapy.

E E Wanker1.   

Abstract

The accumulation of highly insoluble intracellular protein aggregates in neuronal inclusions is a hallmark of Huntington's disease (HD) and Parkinson's disease (PD) as well as several other late-onset neurodegenerative disorders. The aggregates formed in vitro and in vivo generally have a fibrillar morphology, consist of individual beta-strands and are resistant to proteolytic degradation. Although the causal relationship between aggregate formation and disease remains to be proven, the gradual deposition of mutant protein in neurons is consistent with the late-onset and progressive nature of symptoms. Recently, circumstantial evidence from mouse and Drosophila model systems suggests that abnormal protein folding and aggregation play a key role in the pathogenesis of both HD and PD. Therefore, a detailed understanding of the molecular mechanisms of protein aggregation and its effects on neuronal cell death could open new opportunities for therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006527     DOI: 10.1016/s1357-4310(00)01761-5

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  12 in total

1.  Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c.

Authors:  A S Morar; A Olteanu; G B Young; G J Pielak
Journal:  Protein Sci       Date:  2001-11       Impact factor: 6.725

2.  Thermal denaturation of Bungarus fasciatus acetylcholinesterase: Is aggregation a driving force in protein unfolding?

Authors:  I Shin; E Wachtel; E Roth; C Bon; I Silman; L Weiner
Journal:  Protein Sci       Date:  2002-08       Impact factor: 6.725

Review 3.  Developing master keys to brain pathology, cancer and aging from the structural biology of proteins controlling reactive oxygen species and DNA repair.

Authors:  J J P Perry; L Fan; J A Tainer
Journal:  Neuroscience       Date:  2006-12-15       Impact factor: 3.590

Review 4.  The structural biochemistry of the superoxide dismutases.

Authors:  J J P Perry; D S Shin; E D Getzoff; J A Tainer
Journal:  Biochim Biophys Acta       Date:  2009-11-13

5.  PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.

Authors:  Na-Li Jia; Er-Kang Fei; Zheng Ying; Hong-Feng Wang; Guang-Hui Wang
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

6.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

7.  Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay.

Authors:  Volker Heiser; Sabine Engemann; Wolfgang Bröcker; Ilona Dunkel; Annett Boeddrich; Stephanie Waelter; Eddi Nordhoff; Rudi Lurz; Nancy Schugardt; Susanne Rautenberg; Christian Herhaus; Gerhard Barnickel; Henning Böttcher; Hans Lehrach; Erich E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-28       Impact factor: 11.205

8.  Stabilization of a metastable state of Torpedo californica acetylcholinesterase by chemical chaperones.

Authors:  Charles B Millard; Valery L Shnyrov; Simon Newstead; Irina Shin; Esther Roth; Israel Silman; Lev Weiner
Journal:  Protein Sci       Date:  2003-10       Impact factor: 6.725

Review 9.  Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.

Authors:  Andreas Wyttenbach
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

10.  Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.

Authors:  Manfred Windisch; Birgit Hutter-Paier; Edward Rockenstein; Makoto Hashimoto; Margaret Mallory; Eliezer Masliah
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.